Search results
Results From The WOW.Com Content Network
Eastman Kodak (1988 to 1994) Sterling Drug was an American based global pharmaceutical company. It was also known as Sterling Winthrop, Inc., after the merger with Winthrop-Stearns Inc. which itself resulted from the merger of Winthrop Chemical Company Inc. and Frederick Stearns & Company. It was formerly known as Sterling Winthrop Pharmaceuticals.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd [3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.
Bayer AG ( English: / ˈbaɪ.ər /, commonly pronounced / ˈbeɪər /; [3] German: [ˈbaɪɐ]) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include: pharmaceuticals, consumer ...
In addition to the price limit for people on private insurance, Sanofi will also lower the list price of Lantus by 78% and its short-acting insulin Apidra by 70%. Those moves will benefit people ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Paris-based Sanofi's CEO Chris Viehbacher provided a possible price range of $69 to $80 a share when he met the Genzyme's CEO Henri Termeer at a Sept. 20 meeting. Termeer declined to agree to the ...
Sanofi-Aventis will pay Covance between $1.2 billion to $2.2 billion. ... the primary one being the large gap in price between what Genzyme thinks it's worth and what Sanofi is willing to pay.
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2] [3] [4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...